Emmaus Life Sciences, Inc. (EMMA)
USD 0.02
(-12.28%)
USD 0.02
(-12.28%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.73 Million USD | 65.06% |
| 2022 | -10.68 Million USD | 32.99% |
| 2021 | -15.94 Million USD | -1277.7% |
| 2020 | 1.35 Million USD | 102.47% |
| 2019 | -54.84 Million USD | -471.35% |
| 2018 | -9.59 Million USD | -34.95% |
| 2017 | -7.11 Million USD | -19.73% |
| 2016 | -5.94 Million USD | -75.8% |
| 2015 | -3.37 Million USD | -26.91% |
| 2014 | -2.66 Million USD | 75.59% |
| 2013 | -10.9 Million USD | -220.17% |
| 2012 | -3.4 Million USD | 61.58% |
| 2011 | -8.86 Million USD | -8.47% |
| 2010 | -8.17 Million USD | 4.09% |
| 2009 | -8.52 Million USD | -58.66% |
| 2008 | -5.37 Million USD | -63.81% |
| 2007 | -3.27 Million USD | -652.88% |
| 2006 | -435.53 Thousand USD | -2012.32% |
| 2005 | -20.61 Thousand USD | 92.26% |
| 2004 | -266.39 Thousand USD | -90.21% |
| 2003 | -140.05 Thousand USD | -1103.97% |
| 2002 | -11.63 Thousand USD | -13.32% |
| 2001 | -10.26 Thousand USD | -30.59% |
| 2000 | -7861.00 USD | 80.35% |
| 1999 | -40 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -4.34 Million USD | -459.64% |
| 2024 Q2 | -2.18 Million USD | 49.77% |
| 2023 Q4 | 1.2 Million USD | 1704.48% |
| 2023 Q2 | -1.48 Million USD | 57.98% |
| 2023 Q1 | -3.52 Million USD | -1863.5% |
| 2023 FY | -3.73 Million USD | 65.06% |
| 2023 Q3 | 67 Thousand USD | 104.52% |
| 2022 Q3 | -391 Thousand USD | 95.6% |
| 2022 Q4 | 200 Thousand USD | 151.15% |
| 2022 FY | -10.68 Million USD | 32.99% |
| 2022 Q1 | -1.54 Million USD | 77.53% |
| 2022 Q2 | -8.89 Million USD | -476.65% |
| 2021 Q3 | -3.15 Million USD | -226.6% |
| 2021 Q2 | 2.48 Million USD | 129.55% |
| 2021 Q1 | -8.42 Million USD | -1516.51% |
| 2021 FY | -15.94 Million USD | -1277.7% |
| 2021 Q4 | -6.86 Million USD | -117.77% |
| 2020 Q2 | -9.47 Million USD | -271.95% |
| 2020 Q1 | 5.5 Million USD | 34.33% |
| 2020 Q3 | 5.58 Million USD | 158.96% |
| 2020 Q4 | -521 Thousand USD | -109.33% |
| 2020 FY | 1.35 Million USD | 102.47% |
| 2019 FY | -54.84 Million USD | -471.35% |
| 2019 Q2 | -2.12 Million USD | 6.06% |
| 2019 Q3 | -26.13 Million USD | -1131.89% |
| 2019 Q1 | -2.25 Million USD | 5.0% |
| 2019 Q4 | 4.1 Million USD | 115.69% |
| 2018 Q4 | -2.37 Million USD | -45.24% |
| 2018 Q2 | -2.6 Million USD | 2.05% |
| 2018 Q1 | -2.65 Million USD | 3.96% |
| 2018 Q3 | -1.63 Million USD | 37.16% |
| 2018 FY | -9.59 Million USD | -34.95% |
| 2017 Q3 | -2.64 Million USD | -68.42% |
| 2017 Q1 | -1.45 Million USD | 0.81% |
| 2017 Q2 | -1.57 Million USD | -8.29% |
| 2017 Q4 | -2.76 Million USD | -4.57% |
| 2017 FY | -7.11 Million USD | -19.73% |
| 2016 Q1 | -142.7 Thousand USD | 95.87% |
| 2016 Q4 | -1.46 Million USD | -47.49% |
| 2016 Q3 | -992.5 Thousand USD | 26.72% |
| 2016 FY | -5.94 Million USD | -75.8% |
| 2016 Q2 | -1.35 Million USD | -849.12% |
| 2015 Q3 | -1.27 Million USD | -136.92% |
| 2015 Q1 | -696.3 Thousand USD | 20.39% |
| 2015 FY | -3.37 Million USD | -26.91% |
| 2015 Q4 | -3.45 Million USD | -171.37% |
| 2015 Q2 | -536.8 Thousand USD | 22.91% |
| 2014 FY | -2.66 Million USD | 75.59% |
| 2014 Q3 | -837.1 Thousand USD | 17.83% |
| 2014 Q4 | -874.6 Thousand USD | -4.48% |
| 2014 Q1 | -942 Thousand USD | -797.26% |
| 2014 Q2 | -1.01 Million USD | -8.15% |
| 2013 Q1 | -1.53 Million USD | -57.21% |
| 2013 FY | -10.9 Million USD | -220.17% |
| 2013 Q3 | -7.06 Million USD | -429.9% |
| 2013 Q4 | 135.1 Thousand USD | 101.91% |
| 2013 Q2 | -1.33 Million USD | 12.82% |
| 2012 Q4 | -973.3 Thousand USD | -123.72% |
| 2012 Q2 | 3.61 Million USD | 143.07% |
| 2012 FY | -3.4 Million USD | 61.58% |
| 2012 Q1 | -8.39 Million USD | -207.34% |
| 2012 Q3 | 4.1 Million USD | 13.51% |
| 2011 Q2 | 873.4 Thousand USD | 112.57% |
| 2011 FY | -8.86 Million USD | -8.47% |
| 2011 Q4 | -2.73 Million USD | -1.3% |
| 2011 Q1 | -6.94 Million USD | -7009.83% |
| 2011 Q3 | -2.69 Million USD | -408.7% |
| 2010 Q2 | -1.5 Million USD | -7.63% |
| 2010 Q1 | -1.39 Million USD | 25.03% |
| 2010 FY | -8.17 Million USD | 4.09% |
| 2010 Q3 | -3.42 Million USD | -128.02% |
| 2010 Q4 | -97.7 Thousand USD | 97.14% |
| 2009 Q3 | -4.02 Million USD | -151.6% |
| 2009 Q4 | -1.85 Million USD | 53.83% |
| 2009 FY | -8.52 Million USD | -58.66% |
| 2009 Q1 | -1.46 Million USD | -2.05% |
| 2009 Q2 | -1.6 Million USD | -9.53% |
| 2008 Q2 | -1.59 Million USD | -22.02% |
| 2008 Q1 | -1.3 Million USD | -29.65% |
| 2008 Q4 | -1.43 Million USD | 1.85% |
| 2008 FY | -5.37 Million USD | -63.81% |
| 2008 Q3 | -1.45 Million USD | 8.58% |
| 2007 FY | -3.27 Million USD | -652.88% |
| 2007 Q4 | -1 Million USD | 36.15% |
| 2007 Q3 | -1.58 Million USD | -214.3% |
| 2007 Q1 | -1.46 Million USD | -1060.13% |
| 2007 Q2 | -502.7 Thousand USD | 65.79% |
| 2006 Q4 | -126.67 Thousand USD | -96.64% |
| 2006 Q3 | -64.42 Thousand USD | 72.16% |
| 2006 Q2 | -231.36 Thousand USD | -1668.84% |
| 2006 Q1 | -13.08 Thousand USD | -199.9% |
| 2006 FY | -435.53 Thousand USD | -2012.32% |
| 2005 Q2 | -6860.00 USD | 55.64% |
| 2005 FY | -20.61 Thousand USD | 92.26% |
| 2005 Q4 | 13.09 Thousand USD | 214.96% |
| 2005 Q3 | -11.38 Thousand USD | -66.02% |
| 2005 Q1 | -15.46 Thousand USD | 85.79% |
| 2004 Q4 | -108.84 Thousand USD | 24.44% |
| 2004 FY | -266.39 Thousand USD | -90.21% |
| 2004 Q1 | -3195.00 USD | 22.55% |
| 2004 Q3 | -144.06 Thousand USD | -469.51% |
| 2004 Q2 | -25.29 Thousand USD | -691.74% |
| 2003 FY | -140.05 Thousand USD | -1103.97% |
| 2003 Q1 | -2714.00 USD | 33.55% |
| 2003 Q4 | -4125.00 USD | 92.88% |
| 2003 Q3 | -57.95 Thousand USD | 22.99% |
| 2003 Q2 | -75.26 Thousand USD | -2673.07% |
| 2002 Q1 | -3462.00 USD | 1.87% |
| 2002 FY | -11.63 Thousand USD | -13.32% |
| 2002 Q4 | -4084.00 USD | -137.58% |
| 2002 Q3 | -1719.00 USD | 27.38% |
| 2002 Q2 | -2367.00 USD | 31.63% |
| 2001 Q2 | -572.00 USD | 89.44% |
| 2001 FY | -10.26 Thousand USD | -30.59% |
| 2001 Q1 | -5417.00 USD | 45.83% |
| 2001 Q4 | -3528.00 USD | -371.03% |
| 2001 Q3 | -749.00 USD | -30.94% |
| 2000 Q4 | -10 Thousand USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 FY | -7861.00 USD | 80.35% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 1999 FY | -40 Thousand USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 Q3 | - USD | 100.0% |
| 1999 Q2 | -10 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -179.535% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 46.54% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 107.046% |
| Nascent Biotech, Inc. | -2.08 Million USD | -78.811% |
| Rebus Holdings, Inc. | -1.02 Million USD | -265.98% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 105.731% |
| Qrons Inc. | -789.34 Thousand USD | -372.923% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -490.284% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 94.037% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -798.481% |
| Skye Bioscience, Inc. | -37.64 Million USD | 90.084% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 95.02% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 43.234% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1265.389% |
| SQZ Biotechnologies Company | -79.46 Million USD | 95.302% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -29.063% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -105.05% |
| Mesoblast Limited | -87.95 Million USD | 95.756% |
| Marizyme, Inc. | -65.34 Million USD | 94.287% |
| Genus plc | 7.9 Million USD | 147.253% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 65.726% |
| Pharming Group N.V. | -10.54 Million USD | 64.609% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -72.042% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -0.614% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 57.791% |
| ContraFect Corporation | -65.15 Million USD | 94.27% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 23.599% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -116.098% |
| IMV Inc. | -36.48 Million USD | 89.769% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 53.683% |
| MultiCell Technologies, Inc. | -380.07 USD | -982087.492% |
| ONE Bio Corp. | 8.67 Million USD | 143.024% |
| Accustem Sciences Inc. | -3.74 Million USD | 0.358% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 92.778% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -194.602% |
| Q BioMed Inc. | -2.05 Million USD | -81.912% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -56.791% |
| Biomind Labs Inc. | -1.21 Million USD | -207.415% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 93.75% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -20.351% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 52.765% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -91.51% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -24826.549% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 76.48% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 35.829% |
| GB Sciences, Inc. | -1.36 Million USD | -174.147% |
| Alpha Cognition Inc. | -13.77 Million USD | 72.895% |
| HST Global, Inc. | -146.21 Thousand USD | -2453.177% |
| CSL Limited | 2.64 Billion USD | 100.141% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -112.734% |
| Halberd Corporation | -79.67 Thousand USD | -4585.225% |
| Enzolytics Inc. | -2.17 Million USD | -71.488% |
| Agentix Corp. | -1.37 Million USD | -171.647% |
| Resverlogix Corp. | -3.61 Million USD | -3.407% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -17.707% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 98.735% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 3909.184% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 153.909% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 6.041% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -23.359% |
| AVAX Technologies, Inc. | -6.41 Million USD | 41.796% |
| Zenith Capital Corp. | -10.59 Million USD | 64.77% |
| Genscript Biotech Corporation | -95.47 Million USD | 96.09% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -15961.44% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 9.96% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -6076.311% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -86.174% |
| Kadimastem Ltd | -3.3 Million USD | -12.868% |
| Helix BioMedix, Inc. | -1.05 Million USD | -253.485% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 2.252% |
| BioStem Technologies, Inc. | -8.48 Million USD | 55.994% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -745.778% |
| LadRx Corporation | 400.44 Thousand USD | 1032.218% |
| Cell Source, Inc. | -5.32 Million USD | 29.847% |
| Regen BioPharma, Inc. | 1.02 Million USD | 464.726% |
| Regen BioPharma, Inc. | 1.02 Million USD | 464.726% |
| NovAccess Global Inc. | -4.76 Million USD | 21.727% |
| Affymax, Inc. | -14.42 Million USD | 74.12% |
| Itoco Inc. | -1.86 Million USD | -99.733% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 15.971% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -123.667% |
| Mobile Lads Corp. | -2.26 Million USD | -64.937% |
| CytoDyn Inc. | -49.84 Million USD | 92.51% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -4623.343% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1536.369% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -296.483% |
| SYBLEU INC | -180.3 Thousand USD | -1970.392% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -131.47% |
| International Stem Cell Corporation | -131 Thousand USD | -2749.618% |
| Bioxytran, Inc. | -4.28 Million USD | 12.78% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -6778.317% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -47.535% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 92.235% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -76.585% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -378.046% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -17.835% |
| Neutra Corp. | -233.46 Thousand USD | -1498.955% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 81.603% |
| PureTech Health plc | -65.69 Million USD | 94.318% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 82.447% |
| IXICO plc | -1.17 Million USD | -216.893% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 62.395% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 93.466% |
| CSL Limited | 2.64 Billion USD | 100.141% |
| Cellectis S.A. | -103.17 Million USD | 96.382% |